Beattie R M, Nicholls S W, Domizio P, Williams C B, Walker-Smith J A
Department of Paediatric Gastroenterology, Medical College of St. Bartholomew's Hosptial, London, England.
J Pediatr Gastroenterol Nutr. 1996 May;22(4):373-9. doi: 10.1097/00005176-199605000-00006.
Twenty children with active ulcerative colitis were assessed before and after 8 weeks of medical therapy with 5-aminosalicylic acid (5-ASA) derivatives and corticosteroids. Local therapy was given for distal disease (seven cases); other disease was treated with oral prednisolone (1-2 mg/kg/day, maximum 40 mg). Eighteen of the children showed a clinical improvement on therapy, and complete remission of clinical disease activity by 8 weeks was seen in 17 (85%). C-reactive protein was elevated initially in 10 of 20 children and returned to normal posttreatment in all but one. Reassessment of the colon after treatment showed an improved endoscopic appearance in 15 and complete remission in eight (40%). Histological improvement was seen in 13, with full remission in only three (15%). In conclusion, remission of clinical disease activity by corticosteroid therapy in ulcerative colitis may not be accompanied by endoscopic remission and uncommonly by mucosal healing. This finding may be important prognostically because of the risk of dysplasia in long-standing persistent mucosal inflammation.
对20例活动性溃疡性结肠炎患儿在接受5-氨基水杨酸(5-ASA)衍生物和皮质类固醇药物治疗8周前后进行了评估。对远端病变患儿(7例)进行了局部治疗;其他病变患儿采用口服泼尼松龙治疗(1-2mg/kg/天,最大剂量40mg)。18例患儿治疗后临床症状改善,17例(85%)在8周时临床疾病活动完全缓解。20例患儿中10例最初C反应蛋白升高,除1例患儿外,其余患儿治疗后均恢复正常。治疗后对结肠进行重新评估,15例患儿内镜表现改善,8例(40%)完全缓解。13例患儿组织学改善,仅3例(15%)完全缓解。总之,皮质类固醇治疗溃疡性结肠炎使临床疾病活动缓解时,可能未伴有内镜缓解,黏膜愈合则更为少见。这一发现可能在预后方面具有重要意义,因为长期持续性黏膜炎症存在发育异常的风险。